These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17700016)

  • 1. Non-cardiovascular mortality, low-density lipoprotein cholesterol and statins: a meta-regression analysis.
    Razzolini R; Tarantini G; Ossena G; Favaretto E; Bilato C; Manzato E; Dalla-Volta S; Iliceto S
    Cardiology; 2008; 109(2):110-6. PubMed ID: 17700016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins, low-density lipoprotein cholesterol, and risk of cancer.
    Alsheikh-Ali AA; Trikalinos TA; Kent DM; Karas RH
    J Am Coll Cardiol; 2008 Sep; 52(14):1141-7. PubMed ID: 18804740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis.
    Robinson JG; Smith B; Maheshwari N; Schrott H
    J Am Coll Cardiol; 2005 Nov; 46(10):1855-62. PubMed ID: 16286171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis.
    Kinlay S
    J Am Coll Cardiol; 2007 May; 49(20):2003-9. PubMed ID: 17512355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
    van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
    Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LDL-cholesterol differences predicted survival benefit in statin trials by the surrogate threshold effect (STE).
    Johnson KR; Freemantle N; Anthony DM; Lassere MN
    J Clin Epidemiol; 2009 Mar; 62(3):328-36. PubMed ID: 18834708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuation of statin treatment and all-cause mortality: a population-based cohort study.
    Shalev V; Chodick G; Silber H; Kokia E; Jan J; Heymann AD
    Arch Intern Med; 2009 Feb; 169(3):260-8. PubMed ID: 19204217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival.
    Leeper NJ; Ardehali R; deGoma EM; Heidenreich PA
    Circulation; 2007 Aug; 116(6):613-8. PubMed ID: 17664373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
    Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of statin medications on prostate-specific antigen levels.
    Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report.
    Fukuta H; Sane DC; Brucks S; Little WC
    Circulation; 2005 Jul; 112(3):357-63. PubMed ID: 16009792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of statins on risk of stroke: a meta-analysis.
    Henyan NN; Riche DM; East HE; Gann PN
    Ann Pharmacother; 2007 Dec; 41(12):1937-45. PubMed ID: 17986516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-density lipoprotein cholesterol increase and non-cardiovascular mortality: a meta-analysis.
    Burillo E; Andres EM; Mateo-Gallego R; Fiddyment S; Jarauta E; Cenarro A; Civeira F
    Heart; 2010 Sep; 96(17):1345-51. PubMed ID: 20801853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.